Don’t Stop Relieving: Journey’s DFD-29 Trounces Oracea In Reducing Rosacea Lesions

The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.

Journey announced topline results from two Phase III rosacea trials • Source: Shutterstock

Journey Medical Corp.’s DFD-29, partnered with Dr. Reddy's Laboratories Ltd., has potential to claim a significant share of the papulopustular rosacea market, which Galderma S.A.’s Oracea (doxycycline) currently dominates, having originally won US Food and Drug Administration approval in 1967. Topline results from Phase III clinical trials showed a statistically significant efficacy advantage for the drug over both Oracea and placebo in terms of reducing lesion count in adult patients with the skin condition.

Journey announced results from the MVOR-1 and MVOR-2 trials on 11 July, stating that both achieved their co-primary endpoints of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Dynavax Aims To Disrupt GSK’s Shingrix Market With More Tolerable Shingles Vaccine

21 Aug 2025

• By Mandy Jackson

Phase I/II head-to-head data show Dynavax’s Z-1018 had similar immunogenicity and much improved tolerability versus Shingrix, prompting a move into Part 2 of the study.

Nicox Plots US Submission After Another Phase III Glaucoma Win

21 Aug 2025

• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

20 Aug 2025

• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Celldex Bullish On Barzolvolimab Despite Study Miss

20 Aug 2025

• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

20 Aug 2025

• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.